Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
ATP is a marker for cell viability due to its presence in all metabolically active cells. ATP concentration declines rapidly when cells undergo necrosis or apoptosis, and so monitoring ATP is a good indicator of cytotoxic, cytostatic and proliferation effects.
Our ATPlite 1step ATP luminescence assays use patented technologies to measure cell proliferation and cytotoxicity in mammalian cells based on the production of light caused by the reaction of ATP with added luciferase and D-luciferin.
Features and benefits:
An alternative format of this assay is also available. The ATPlite assay has separate cell lysis and luminescent signal generation steps. This allows for a more stable signal, with half-life of at least 4 hours.
|Experimental Type||In vitro|
|Product Brand Name||ATPlite|
|Unit Size||100 mL|
In this application note, we demonstrate an efficient cell-based workflow for the assessment of EGF treatment effects in a cellular model of human skin cancer.
Treatment effects on several intracellular signaling pathways were examined using PerkinElmer’s homogeneous, no-wash AlphaLISA® SureFire® Ultra assays. To determine concurrent time-dependent effects of different EGF concentrations on cellular health and proliferation, ATP concentrations were assessed with ATPlite™ 1step luminescence assay and cultures were fluorescently labeled, imaged and analyzed using the Operetta CLS™ high-content analysis system.
Breast cancer tumors can adapt to immune cell infiltration by responding to the increased concentration of interferon gamma (IFN-ɣ) and other cytokines secreted by subsets of T lymphocytes with the upregulation of the immune checkpoint proteins such as Programmed cell death ligand 1 (PD-L1). These checkpoint proteins allow the tumors to evade immune targeting and reduce the immune response, thus promoting tumor progression.
In this application note, you will learn:
Various cytokines are secreted during an active immune response that can have modulatory effects on target cell populations, including interferon gamma (IFN-ɣ), tumor necrosis factor alpha (TNFa) and several interleukins.
In this application note, you will learn how we investigated:
Over these last few decades there has been a growing trend in drug discovery to use cellular systems and functional assays, in addition to biochemical assays, for the characterization of new potential therapeutics. The ability to study the interaction between a candidate drug and its target within the context of a whole, intact cell allows for more physiologically relevant data to be obtained. However, such assays are more complex than traditional biochemical assays as such facts as membrane permeability, cellular metabolism, cell variability, additional binding partners, and signal transduction must be considered.
To help you navigate the complexities in designing cell-based assays, we have gathered insights collected over the years and compiled them to provide you with elements to consider when setting up your cell-based assays. After all, any assay, biochemical or cell-based, is only as good as its design.